Publication

Article

Cardiology Review® Online

May 2008
Volume25
Issue 5

Decreasing the risk of heart failure in a patient with hypertension and left ventricular hypertrophy

A 60-year-old man presented to his physician's office for a routine visit.

A 60-year-old man presented to his physician's office for a routine visit. He did not have any specific symptoms, chest pain, shortness of breath, palpitations, orthopnea, paroxysmal nocturnal dyspnea, or history of lower extremity edema. He had been told in the past that he had high blood pressure, but had always tried to manage it with diet and exercise, and was not taking any medication. He stated that his father had hypertension and heart failure.

His seated blood pressure was 170/100 mm Hg, with a pulse of 80 beats/minute. He had normal jugular venous pressure, and his lungs were clear on auscultation. He had a regular heart rate and rhythm, with no murmurs; a laterally displaced point of maximal impulse; and no lower extremity edema. Laboratory testing showed normal blood chemistries and complete blood count. An electrocardiogram (ECG) showed normal sinus rhythm at a rate of 80 beats/minute, normal axis deviation, no evidence of prior myocardial infarction, and left ventricular hypertrophy (LVH) by Cornell voltage-duration product criteria (R in aVL of 12 mm, S in V3 of 18 mm, and QRS duration of 100 msec; Cornell voltage-duration product of 3,000 mm·msec).

The patient was started on losartan (Cozaar) 50 mg daily with the addition of hydrochlorothiazide (Hydrodiuril, Microzide, Oretic) 12.5 mg in 1 month, and his blood pressure decreased to 130/80 mm Hg. An ECG performed at 1 year follow-up showed a Cornell voltage-duration product of 2,538 mm·msec (R in aVL of 11 mm, S in V3 of 16 mm, and QRS duration of 94 msec).

According to the results presented in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, this patient should have a 36% lower likelihood of developing heart failure compared with a patient who did not have a regression in Cornell voltage product of at least 236 mm·msec. This patient should be continued on his blood pressure regimen and receive annual ECGs to monitor for further reduction in LVH, thereby decreasing the likelihood of heart failure.

Related Videos
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.